

1 **Optimizing delivery strategies for 3HP TB preventive treatment in Tanzania: A**
2 **qualitative study on acceptability of family approach in HIV care and treatment**
3 **centers**

4 Doreen Pamba^{1*}, Erica Sanga², Killian Mlalama¹, Lucas Maganga¹, Chacha Mangu¹,
5 Anange Lwilla¹, Willyhelmina Olomi¹, Lilian Tina Minja¹, Issa Sabi¹, Riziki Kisonga³,
6 Emmanuel Matechi³, Isaya Jelly⁴, Peter Neema³, Anath Rwebembera⁴, Said Aboud⁵,
7 Nyanda Elias Ntinginya¹

8 ¹National Institute for Medical Research-Mbeya Medical Research Center, Mbeya,
9 Tanzania

10 ²National Institute for Medical Research-Mwanza Medical Research Center, Mwanza,
11 Tanzania

12 ³National Tuberculosis and Leprosy Programme, Ministry of Health, Dodoma, Tanzania

13 ⁴ National AIDS, STIs & Hepatitis Control Programme, Ministry of Health, Dodoma,
14 Tanzania

15 ⁵ National Institute for Medical Research, Dar es Salaam, Tanzania

16 [*dpamba@nimr-mmrc.org](mailto:dpamba@nimr-mmrc.org)

17 DP pambadoreen@gmail.com

18 ES ericass80@hotmail.com

19 KM kmlalama@nimr-mmrc.org

20 LM lmaganga@nimr-mmrc.org

21 CM cmangu@nimr-mmrc.org

22 AL alwillla@nimr-mmrc.org

23 WO wolomi@nimr-mmrc.org

24 LTM tminja@nimr-mmrc.org

25 IS isabi@nimr-mmrc.org

26 RK kisonga2002@gmail.com

27 EM matechi@gmail.com

28 IJ isaiahs@yandex.ru

29 PN pneema36@gmail.com

30 AR arwebembera2@gmail.com

31 SA said.aboud@nimr.or.tz

32 NEN nelias@nimr-mmrc.org

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **Abstract**

49

50 **Introduction:** Tanzania rolled-out a 12-dose, weekly regimen of isoniazid plus
51 rifapentine (3HP) TB preventive treatment in January, 2024. Although 3HP completion
52 rate is generally $\geq 80\%$, variations exist depending on type of delivery strategy and
53 programmatic setting. Prior to the roll-out, a mixed methods study was conducted to
54 assess whether a family approach involving family member support, SMS reminders
55 and three health education sessions, was acceptable and optimized 3HP uptake and
56 completion. This paper describes acceptability of the family approach among people
57 living with HIV (PLHIV), treatment supporters (TS) and community health workers
58 (CHWs).

59 **Methods:** This was a qualitative descriptive study in 12 HIV care and treatment centers
60 across six administrative regions. We purposively sampled 20 PLHIV, 12 CHWs for in-
61 depth interviews and 23 TS for three focus group discussions held between September
62 to December, 2023. The theoretical framework of acceptability guided thematic-content
63 analysis using a framework approach.

64 **Results:** Participants understood that PLHIV have high risk for active TB and that 3HP
65 provides shortened treatment for TB disease prevention. They reported gaining TB and
66 3HP knowledge from health education sessions. However, participation of TS in health
67 education sessions was low and many reported expensive transportation costs to
68 clinics. Receiving support from someone close and SMS were perceived as good
69 adherence reminders. The majority reported mild self-limiting side effects but expressed
70 positive attitudes because of the shortened treatment, TB counselling, satisfaction from
71 helping others, alignment with lifestyle and work responsibilities and reduced work
72 burden. Some PLHIV reported difficulties in identifying family members for support thus,
73 chose other close friends or CHWs.

74 **Conclusions:** Delivery of 3HP with support from family members and SMS reminders is
75 widely accepted by CHWs, PLHIVs and TS. Restricting support from only family

76 members was unacceptable and attendance of all three health education sessions by
77 TS may not be feasible.

78 **Keywords:** 3HP, acceptability, qualitative, TB preventive treatment, family approach,
79 Tanzania

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98 Introduction

99 The co-infection of tuberculosis (TB) and human immunodeficiency virus (HIV) globally
100 remains to be a public health problem and a leading cause of deaths among people
101 living with HIV (PLHIV)(1). Global TB-related deaths among PLHIV were estimated at
102 190,000 in 2021, a stabilizing trend since 2019 (2). PLHIV are 18 times more likely to
103 become infected with TB and develop active TB than the general population due to the
104 weakened immune system (3). In 2022, PLHIV co-infected with TB contributed to 6.3%
105 of the 10.6 million global TB incident cases (4).

106 WHO recommends TB preventive treatment (TPT) for prevention of active TB disease
107 among PLHIV, household contacts of bacteriologically confirmed pulmonary TB persons
108 and clinical risk groups such as those receiving dialysis (4,5).The efficacy of available
109 range of TPT regimens is documented to be 60% to 90% (5). The 2018 United Nations
110 High-Level Meeting (UNHLM) on TB committed to expand global TPT coverage to 6
111 million PLHIV by 2022 (6).Although 11.3 million PLHIV worldwide were reported to have
112 received TPT in 2022 thus exceeding the 2018 UNHLM target of 6 million, a drop of
113 300,000 PLHIV on TPT was observed between 2021 and 2022 (4).

114 Tanzania uses isoniazid preventive treatment (IPT) for prevention of active TB disease
115 among PLHIV since 2010 (7). The IPT involves the use of self-administered isoniazid
116 daily for 6 to 9 months (8,9). In 2022, IPT coverage and completion rates were reported
117 to be 84% and 79%, higher than the national coverage and completion targets of
118 70%and 70%in the same year (10). Countries are recommended by WHO to adopt
119 short course rifamycin-containing TPT regimens (1 to 4 months) that are evidenced to
120 be equally effective, with less hypertoxicity and higher completion rates compared to
121 IPT (5,11,12). The 3HP is among the recommended shorter TPT regimen that involves
122 taking Isoniazid and rifapentine once weekly for 12 weeks. The WHO TPT
123 recommendations of 2020 acknowledge existence of limited evidence on 3HP self-
124 administration (SAT) thus, calling upon additional research including those of digital
125 technologies for adherence support (5). This implies that evidence is needed for novel
126 strategies optimizing delivery of 3HP in routine HIV care settings.

127 Overall, many studies have documented 3HP completion to be $\geq 80\%$, higher than SAT
128 IPT in varied TB burden countries under research or routine conditions and have
129 assessed varied 3HP delivery strategies such as; direct observed therapy (DOT), video
130 directly observed therapy (VDOT), SAT alone, SAT with text reminders and facilitated
131 SAT with few conditional clinic visits for DOT (11,13–15). However, 3HP completion
132 rates vary depending on type of delivery strategy and programmatic setting. A study
133 conducted in United States, Spain, Hong Kong and South Africa showed decreasing
134 treatment completion rates with 3HP DOT (87.2%), 3HP SAT with text reminders
135 (76.4%) and 74.0% with 3HP SAT alone (16). Nevertheless, 3HP SAT has better
136 completion rate and is cost-effective compared to IPT (17).

137 The Tanzanian Ministry of Health had prepared to roll-out 3HP under the guidance of
138 feasibility and acceptability studies (18). Other than DOT, evidence is limited on optimal
139 strategies for delivering 3HP that are feasible and acceptable in Sub-Sahara African
140 programmatic settings. We thus, planned to identify optimized 3HP delivery strategies to
141 support informed decisions on appropriate adherence support strategies during
142 programmatic adoption. We piloted a package of interventions collectively known as a
143 family approach to 3HP to determine acceptability, feasibility and impact on uptake,
144 adherence and completion among PLHIV within the context of a sequential explanatory
145 mixed methods research. As part of the mixed methods research, this paper reports the
146 qualitative component that aimed to assess acceptability of the family approach to 3HP
147 among community health workers (CHWs), PLHIV and their treatment supporters (TS).
148 The full details of the quantitative results will be published separately.

149 **The family approach to 3HP**

150 This approach involves the use of a package of three 3HP delivery strategies in
151 supporting PLHIV with adherence and completion of 3HP as well as adverse events
152 monitoring. Taken together, the piloted strategies were aimed to improve uptake of 3HP
153 compared to the standard 6 months IPT. They included; the use of a family member
154 identified by PLHIV, automated SMS alerts sent to PLHIV and their treatment
155 supporters and the administration of three TPT health education sessions (enrolment,
156 months 2 and 3). The automated SMS alerts were shared daily for adverse events

157 monitoring, weekly for medication adherence and monthly for clinic visit reminders only
158 to the PLHIV and their treatment supporters who had consented.

159 The package of interventional strategies was studied in a prospective cohort under
160 implementation research. It was implemented within 12 randomly selected high-volume
161 HIV care and treatment centers (CTCs) of public owned health facilities across 6
162 purposively selected regions of high HIV prevalence in the country. The cohort formed a
163 quantitative component of a sequential explanatory mixed methods design implemented
164 between May to December 2023. The inclusion criteria for the study participants
165 included; PLHIV enrolled into care within the 12 study CTCs on or after April 2018 to
166 March, 2023 who have identified treatment supporters willing to attend 3 health
167 education sessions as well as those who have completed TB treatment but have not
168 started TPT at the time of study recruitment. PLHIV diagnosed with active TB, with
169 contraindications to rifamycin based drugs or isoniazid, who were already on TPT at the
170 time of study recruitment or were unwilling to use 3HP were excluded from participation.
171 The participants were given 3HP weekly for 3 months, commencing on the 14th day
172 post-HIV diagnosis.

173 **Theoretical framework**

174 The theoretical framework of acceptability (TFA) was adopted to guide the content of
175 data collection tools, data analysis as well as interpretation of experienced acceptability
176 of the family approach to 3HP. The TFA constitutes seven constructs that inform
177 qualitative assessment of acceptability of health interventions. These include;
178 intervention coherence, self-efficacy, perceived effectiveness, affective attitude,
179 ethicality, burden and opportunity costs(19).The constructs were operationalized to fit
180 the context of this study thus, two of the constructs i.e., burden and opportunity cost
181 were merged and assessed together. We sought to assess the extent to which
182 participants understood TB, TPT, the rationale of the family approach to 3HP/3RH and
183 how it works (intervention coherence), participants' perceptions of how confident they
184 felt in assuming the roles of treatment supporters/CHWs or in adhering to TPT (self-
185 efficacy), participants' perceptions of the extent to which the family approach
186 intervention will improve uptake of 3HP (perceived effectiveness), participants' feelings

187 about being a treatment supporter/ CHW to TPT use or feelings about using TPT
188 (affective attitude), the extent to which the roles of treatment supporters/CHWs or the
189 use of 3HP fits well with lifestyle and work responsibilities (ethicality) as well as efforts
190 and challenges encountered in the implementation of different components of the family
191 approach package (burden/opportunity cost).

192 **Methods**

193 **Study design**

194 This was a qualitative descriptive study conducted as part of a sequential explanatory
195 mixed methods study. The design enabled us to generate in-depth information
196 regarding perceptions of CHWs, PLHIV and their treatment supporters to understand
197 whether the family approach package to 3HP/3RH was acceptable. Furthermore, it
198 provides additional information that explains results obtained from the quantitative
199 component of the overall mixed methods study that will be published elsewhere.

200 **Study setting**

201 Qualitative research was conducted in 12 CTCs that were randomly selected to enroll
202 clients into the 3HPTPT across 6 regions in the country namely; Dar es Salaam (Tegeta
203 dispensary and Amana regional referral hospital), Mbeya (Mbalizi designated district
204 hospital and Matundasi dispensary), Iringa (Ngome health center and Mafinga district
205 hospital), Njombe (Njombe town council health center and St. Consolata hospital,
206 Ikonda), Tabora (Tura dispensary and Igunga district hospital) and Mwanza (Misasi
207 health center and Buhongwa dispensary). Permission to conduct the study within the
208 CTC settings was sought from respective health facility authorities.

209

210 **Participants and sampling**

211 The study population consisted of three different groups of participants who were
212 purposively sampled namely: PLHIV enrolled into care in selected study CTCs and their
213 treatment supporters as well as supporting CHWs in the respective CTCs. We recruited

214 20 PLHIV across the 12 study CTCs and who had used 3HP for more than a month.
215 Furthermore, 23 treatment supporters of PLHIV were recruited by HCWs based on their
216 convenience. We maintained a list of CHWs supporting each CTC thus, 12 CHWs from
217 each of the CTCs were recruited.

218 **Data collection**

219 Data were collected between 14th September 2023 to 9th December 2023 by trained
220 social scientists experienced in qualitative research. Semi-structured in-depth interviews
221 (IDIs) and focus group discussions (FGDs) were adopted as data collection tools. They
222 were consented for audio-recording and were conducted in Swahili for an average of 40
223 minutes and 90 minutes respectively. A total of 32 IDIs were held whereby; 20 were
224 engaged with PLHIV and 12 with CHWs. Three FGDs of 7 to 8 participants were
225 conducted with 23 treatment supporters of PLHIVs enrolled in 4 CTCs. All IDIs and
226 FGDs were held in the respective CTCs at locations that guaranteed privacy and were
227 convenient for the participants.

228 The IDI and FGD guides included topics focused around the seven constructs of the
229 TFA in order to inform interpretations on the extent to which the family approach to
230 3HP/3RH was acceptable to participants. These were composed of questions on
231 knowledge of the family approach package and rationale, confidence in implementing
232 respective roles of the intervention, perceptions regarding the effectiveness of the
233 intervention, attitudes towards the intervention, challenges encountered in use of the
234 intervention as well as perceptions regarding how the intervention aligned with lifestyle
235 and work responsibilities. However, the sample size was determined by the data
236 saturation point during IDI and FGD sessions.

237 **Data analysis**

238 Three of the six social scientists (DP, ES and KM) engaged in data collection were
239 involved in data analysis. Audio-recordings of IDIs and FGDs were transcribed verbatim
240 and translated into English by respective social scientists who collected the data and
241 who fluent in both English and Kiswahili. We adopted thematic-content analysis using a

242 framework method to analyze the qualitative data. A sample of the translated transcripts
243 from each of the participant groups were exchanged among the social scientists and
244 reviewed to cross-check correctness of verbatim transcription against the audio-
245 recordings by DP & KM. This allowed not only correction of the transcripts but also
246 depth familiarization of the data. Initial versions of codebooks and coding matrices for
247 each participant group were developed by DP based on research questions and the
248 constructs of the TFA. These were later shared to ES and KM whereby revisions were
249 made and agreed as a team. Furthermore, the transcripts were distributed to each of
250 the social scientists for independent coding and charting. Themes were developed
251 based on overarching meanings identified from groups of categories as well as based
252 on grouping TFA constructs interpreted to portray a pattern of similar meaning. The
253 themes were presented in descriptions that included quotations to further illustrate the
254 findings.

255 **Ethical considerations**

256 Ethical approval was sought from the Mbeya Medical Research and Ethics review
257 Committee (MMREC) in Tanzania (*Ref. No. SZEC-2439/R.A/V.1/168*). Written consent
258 was secured from eligible participants prior to engaging in study discussions. We
259 ensured that the study is conducted in full conformity with the current version of the
260 Declaration of Helsinki and with the Tanzanian health research rules, regulations and
261 guidelines

262

263

264

265

266

267

268

269

270

271 **Results**

272 The findings are presented in terms of five themes that relate to the TFA constructs.
273 The these inform our understanding of factors that promoted acceptance of the family
274 approach to 3HP among a majority of participants and those that need to be improved if
275 the approach is to be adopted within programmatic settings.

276 **Demographic characteristics of study participants**

277 Many of the PLHIV (8/20) were enrolled into care in CTCs from hospitals levels. A great
278 proportion had only primary level education (16/20) and many were earning income
279 from farming (8/20) and small businesses (8/20). They had a median age of 38 years
280 and were living with HIV for median duration of 3.5 months. Majority of the treatment
281 supporters were female (14/23) and many were earning income from small businesses
282 (9/23). Many of them supported PLHIV enrolled into care in CTCs from hospitals
283 (13/23). As for the CHWs, many were volunteering to support CTCs from hospital levels
284 (10/12) and half of them (6/12) had primary level education (See Table 1).

Characteristic	N (%)	N (%)	N (%)
	PLHIV	CHW	Treatment supporters
Facility level			
Dispensary	6 (30)	4 (33)	10 (43.5)
Health Center	6 (30)	3 (25)	-
Hospital	8 (40)	5 (42)	13 (56.5)
Sex			
Male	10 (50)	2 (17)	9 (39.1)
Female	10 (50)	10 (83)	14 (60.9)
Age (Median, IQR)	38 years (32-46)	-	-
Education level			
Primary	16 (80)	6 (50)	9 (39.1)
Secondary	1 (0.05)	4 (33)	11 (47.8)
College	1 (0.05)	2 (17)	3 (13.0)
None	2 (0.1)	-	-
HIV duration (Median, IQR)	3.5 months (3-6)	-	-
CHW experience (Median, IQR)		7yrs (5-14)	
CTC working experience (Median, IQR)			
Occupation			
Business person	8 (40)	-	9 (39.1)
Farmer	8 (40)	-	8 (34.8)
Boda boda Driver	1 (0.05)	-	
Construction	1 (0.05)	-	
Mining	1 (0.05)	-	
Mechanics	1 (0.05)	-	
Clerk		-	1 (4.3)
Food vendor		-	1 (4.3)
Tailor		-	1 (4.3)
Mason		-	2 (8.7)
Profession			
Clinician		-	-
Nurse		-	1 (4.3)

285 Table 1: Characteristics of PLHIV, CHWs and treatment supporters

286 **Theme 1: Knowledge about family approach to 3HP**
287 **(intervention coherence)**

288 This theme describes the extent to which CHWs, PLHIV and their treatment supporters
289 understood the rationale of the family approach to TPT and their general understanding
290 of TB and TPT. It relates to the TFA construct of intervention coherence.

291 Many of the PLHIV understood that TB is transmitted through the air and in close
292 proximity to someone who is sick from TB. They reported being educated by HCWs at
293 the time they were diagnosed with HIV. They all knew that they are at risk for TB
294 because of low immunity caused by HIV.

295 *“According to what I was taught here at the clinic, PLHIV are at high risk of*
296 *acquiring TB because our immunity is already low...”* (Female PLHIV, IDI,
297 dispensary).

298 They reported taking 3HP once weekly for three months and understood that TPT is to
299 help them from acquiring TB disease but were unable to narrate details about TB
300 treatment. Few reported being informed of long and short TPT regimens. The quote
301 below narrates a client’s understanding of why she was given TPT:

302 *“I was told by the nurses who gave me those medication, they said that since I*
303 *am HIV positive then my immunity is low so I can be attacked by any disease any*
304 *time, that’s why they gave me TB preventive treatment.”* (Female PLHIV, IDI,
305 dispensary)

306 Furthermore, the PLHIV understood that the family member is someone to support them
307 in medication adherence. They understood that a treatment supporter should be
308 someone close thus, many reported selecting their spouses. These conceptions are
309 illustrated in the quotes below:

310 *“[treatment supporter should] tell him or her that when it reaches certain hours,*
311 *have you taken the medicine or not?”* (Male PLHIV, IDI, dispensary)

312 *"They told me to choose my closest person...the close person I have here is my*
313 *husband, I can't go to another house to find the treatment supporter, that's not*
314 *possible and that's why I preferred my husband"* (Female PLHIV, IDI, health
315 center)

316 However, one of the PLHIV did not see the need or importance of having a treatment
317 supporter as he perceived himself as able to take care of his own health and not
318 needing supervision from someone else

319 *"Personally, I just can't say that you need someone to supervise you so that you*
320 *can take the medicine because this is your own health and when you will take the*
321 *medicine that means you are protecting yourself, you just can't say that until*
322 *someone supervises you that's when you will take the medication, I am taking*
323 *control of my own health so that I can be okay, I don't need anyone to observe*
324 *me"* (Female PLHIV, IDI, health center)

325 Similarly, many of the treatment supporters understood that TB can be transmitted
326 through the air and from someone who hasn't started TB treatment. All of them said that
327 TB is treatable and cured within 6 months of treatment. They mentioned their clients to
328 be at risk for TB disease because of low immunity from HIV and having being educated
329 by HCWs that TPT prevents TB among PLHIV. This is illustrated in the quote below:

330 *"...the preventive treatment is for the person who is not infected with TB.*
331 *Therefore, before he was given those drugs, he was screened for TB by being*
332 *asked for TB signs and symptoms where among the questions I remember one*
333 *was about coughing. After that the doctor said if a person is found with TB cannot*
334 *use preventive therapy and instead can use TB treatment drugs for six months"*
335 (Male Treatment supporter, FGD, dispensary)

336 The treatment supporters understood that the family approach intends to help the client
337 at a family level. They knew that as a treatment supporter, they are supposed to remind
338 their clients about taking medications and also identification and reporting of TPT side
339 effects.

340 *"Sometimes, the patient may not adhere to the treatment. By reminding them,*
341 *they can take their medication without hesitation or quitting. If they encounter any*
342 *challenges, they can seek advice from the treatment supporter before going to*
343 *the healthcare provider"* (Female Treatment supporter, FGD, hospital)

344 *"...as per doctor's instructions it seems my presence to this patient is needed*
345 *because he might get those effects to the extent that he cannot be able to report,*
346 *that makes me as part of the family to report the incidence to the health facility*
347 *that my relative has got such effects for them to assist the patient"* (Male
348 Treatment supporter, FGD, dispensary)

349 All of the CHWs understood that 3HP is a shortened TPT compared to INH and is given
350 to someone confirmed of not having TB/TB symptoms but at risk for TB. They stated
351 that PLHIV have freedom to choose the day and time to take 3HP.

352 *"It is taken for three months, once in a week and the client will choose the*
353 *specific day to take them for example he can choose Wednesday, so every*
354 *Wednesday he will be taking them till three months"* (Female CHW, IDI, health
355 center)

356 The CHWs understood that the family approach intends to use a family member to
357 support TPT adherence which will in turn also protect the family from contracting TB.

358 *"...as you are teaching them sometimes the client might not concentrate due to*
359 *his condition so the treatment supporter will help to remind him that at the*
360 *hospital, we were told about this and that. For example, the client might decide to*
361 *stop taking the medication saying that he is tired but the treatment supporter will*
362 *intervene to tell him that we were insisted that you can't skip any day, so just take*
363 *them, also he will encourage him"* (Female CHW, IDI, health center)

364 However, they reported that a closed one can assume the role of a treatment supporter
365 not necessarily a family member.

366 *"We ask the client to suggest the person he thinks he will be comfortable with like*
367 *who do you think you can disclose to? is it your father, mother, your child, a*
368 *friend or just any one?" (Male CHW, IDI, hospital)*

369 **Theme 2: Confidence in 3HP adherence (self-efficacy)**

370 This theme describes the treatment supporter's confidence that he or she can support
371 his or her client to adhere to TPT. It also describes the confidence of PLHIV in adhering
372 to TPT. As for CHWs and in the context of family approach, it refers to the CHW's
373 confidence that he or she can support his or her client to adhere to TPT and conduct
374 household HIV testing. The theme relates to the TFA construct on self-efficacy.

375 The PLHIV were confident in their ability to adhere to 3HP and clinic visits because they
376 understood that they were at risk for TB.

377 *"I knew that I have already got this [HIV] disease therefore I have low immunity,*
378 *so, I better take the [TB] preventive medicines so as when the [TB] disease*
379 *enters at least find me prevented already"* (Male PLHIV, IDI, dispensary)

380 All treatment supporters reported compelling reasons that influenced their acceptance
381 of offering support. Many of those who were first degree relatives reported an obligation
382 to provide support to the clients based on blood relations and dependability. This was
383 also the case for those who were close friends.

384 *"It was my responsibility to bring my mother to the hospital for treatment when it*
385 *was discovered that she had HIV. So, she needed immune protection to stay*
386 *healthy. I had no fear because I knew it's all part of life's challenges, and she*
387 *needed my support."* (Female Treatment supporter, FGD, hospital)

388 *"In my case, it's my sister who went through this ordeal, and I wasn't advised by*
389 *anyone. But I thought it was better to be together and provide encouragement*
390 *because life unfolds this way. If I had left her alone, she might have suffered*
391 *psychologically."* (Female Treatment supporter, FGD, hospital)

392 One of the treatment supporters was a CHW who stated having empathy for PLHIV who
393 did not have someone close to support him or her thus, being willing to assume the role
394 of a treatment supporter.

395 *"It is when you see people losing their lives, they are suffering because of not*
396 *having a helper or an adviser; that is when I was motivated that whenever it such*
397 *kind of a person happens, I must support him/her...I must encourage him so that*
398 *he uses the medicine to save his life, so that other things in life can proceed"*
399 (Female Treatment supporter, FGD, hospital)

400 Few of the treatment supporters reported feeling motivated to continue supporting
401 treatment because of having clients who remembered taking the drugs on their own
402 prior to being followed up.

403 *" The patient himself has made me confident to continue supporting him well he*
404 *is the one who showed me cooperation by taking medications, he does not afraid*
405 *of taking pills only that my responsibility is to remind him on the day and time to*
406 *take medicines"* (Male Treatment supporter, FGD, dispensary)

407 All of the CHWs felt confident of being able to conduct household HIV counseling and
408 testing because of numerous trainings that they received as well as being known in their
409 communities.

410 *"I can say that I have confidence in myself since I have been doing this*
411 *counseling for a very long time, the more I continue talking to people and various*
412 *facilities the more I gain confidence in counseling, some are even coming to my*
413 *house so that I can offer to them counseling."* (Female CHW, IDI, hospital)

414 *"...I trust my ability because when you want to approach the household, you just*
415 *can't get there and say I have to test on you, no. When you get there, you have*
416 *to explain why you went there, the advantages and disadvantages, after*
417 *narrowing those down then he will understand"* (Female CHW, IDI, dispensary).

418

419 **Theme 3: Perceived effectiveness of family approach** 420 **(perceived effectiveness)**

421 The TFA construct on perceived effectiveness was linked to this theme that describes
422 participant perceptions of the extent to which the family approach will increase uptake of
423 TPT.

424 The PLHIV viewed using a closed one as a treatment supporter is very helpful to
425 support their 3HP adherence. They narrated receiving varied advice, medication
426 reminders and support for food from those whom they selected as their treatment
427 supporters. Many of the PLHIV also mentioned having being given the freedom to
428 choose anyone to support them based on closed relations.

429 *"We normally have discussion with him, he even advises me on what I should*
430 *eat, type of work I should do, sometimes he even sends the texts to remind me*
431 *on different issues related with TPT"* (Male PLHIV, IDI, dispensary)

432 *"... You can choose your relative or your close friend who can keep your secret"*
433 (Male PLHIV, IDI, hospital)

434 The PLHIV viewed using a closed one as a treatment supporter is very helpful to
435 support their 3HP adherence. They narrated receiving varied advice, medication
436 reminders and support for food from those whom they selected as their treatment
437 supporters. Many of the PLHIV also mentioned having being given the freedom to
438 choose anyone to support them based on closed relations.

439 *"We normally have discussion with him [treatment supporter], he even advises*
440 *me on what I should eat, type of work I should do, sometimes he even sends the*
441 *texts to remind me on different issues related with TPT"*(Male cPLHIV, IDI,
442 dispensary)

443 *"... You can choose your relative or your close friend who can keep your secret"*
444 (Male PLHIV, IDI, hospital)

445 They commended on how the SMS texts reminded them to take their pills. Few stated
446 how they felt cared for by the HCWs upon receiving the texts.

447 *"The texts are really helping me... Sometimes I get busy and I might forget to*
448 *take them, but just a short time before my time I would receive the text, So I*
449 *know it's time"* (Female PLHIV, IDI, dispensary)

450 *"I enjoy receiving those texts because I feel that you are caring about me, and*
451 *when I receive a text, I become cautious that I am supposed to do*
452 *something."*(Male PLHIV, IDI, dispensary)

453 All of the PLHIV perceived the health education sessions to have increased their
454 knowledge of TB and TPT. One of the PLHIV stated being influenced to be very careful
455 in preventing oneself from surroundings that would increase his risk for TB
456 transmission.

457 *"The first advantage is that they are giving you the education that you didn't know*
458 *before, and if you really pay attention to them, it helps you...For example, I have*
459 *learned how to protect myself like taking precautions when one is coughing,*
460 *maintaining some distance or when you are in a group of people how should you*
461 *sneeze and other things, so I am paying attention to those details"* (Male PLHIV,
462 IDI, hospital)

463 The treatment supporters perceived the use of automated SMS as a good reminder
464 system for medication intake as the drugs are taken weekly thus, easy to forget.

465 *"It is not always for the human mind you will be thinking about when the patient*
466 *will take medicine, but when I see that message on that day, I do not forget I tell*
467 *her"* (Female Treatment supporter, FGD, health center)

468

469 They stated that health education sessions did not only improve their client's health but
470 also the community as a whole.

471 *"To me, health education helps me in this time and later, because if I will be able*
472 *to let this one not get TB, that means I will be able to support another person, be*
473 *in the family or outside the family which is the general community"* (Female
474 Treatment supporter, FGD, health center)

475
476 One of the treatment supporters perceived the one-to-one health education sessions as
477 challenging and recommended that they are conducted among groups of clients and
478 their treatment supporters.

479 *"...I don't know if they have a system to gather patients together. That's what I*
480 *consider a hindrance because each patient arrives at different times due to their*
481 *different appointments."*(Female Treatment supporter, FGD, hospital)

482 All of the CHWs viewed the automated SMS as good reminders for timely intake of
483 drugs. However, one of them was concerned of clients who were unwilling to receive
484 the texts.

485 *"About the SMS, I think it is a good thing because if the client is taking the*
486 *medication once in a week, then it is easier to forget but once he receives the*
487 *TPT text then it is easier to remember or even if the Treatment supporter*
488 *receives the text, then it is easier for him to remind him..."* (Male CHW, IDI,
489 dispensary)

490 *"There are challenges because some of clients at the beginning refused to be*
491 *sending them these texts...when you ask him, he would say don't send them I*
492 *will remember on my own...He is worried that someone else might see that text"*
493 (Female CHW, IDI, dispensary)

494

495 **Theme 4: Attitudes towards family approach (affective**
496 **attitude and ethicality)**

497 This theme describes feelings about using TPT or feelings about being a supporter for
498 TPT use in the context of the family approach. It relates to the TFA constructs on
499 affective attitude and ethicality.

500 The PLHIV expressed positive attitudes about the different components of the family
501 approach to 3HP. These were attributed to the fact that 3HP is shorter than INH and it
502 prevents them from TB.

503 *"When I heard that this medicine will protect you against acquiring TB and I have*
504 *already witnessed how TB patient is suffering, so I got motivated and I was very*
505 *happy..."* (Female PLHIV, IDI, dispensary).

506 Others felt happy about having a treatment supporter and the counseling they received
507 about TB and TPT at the clinics.

508 *"I thought one day I might get sick to the point that I can't leave my house or*
509 *even take a glass of water, then by having a treatment supporter he can help me*
510 *to come to collect my medication and support me with other issues"*(Male PLHIV,
511 IDI, dispensary)

512 Treatment supporters perceived their role as a blessing to serve people's lives. One of
513 them stated that even the clients consider them as their confidants and supporters to
514 improve not only physical but also psycho-social well-being intended for the patient's
515 health and welfare.

516
517 On the other hand, few treatment supporters mentioned the issue of self-patient stigma
518 against their supporters in the sense that some patients did not accept the supporter to
519 accompany them to the health care facility though they are positive with phone follow-
520 up.

521

522 *"My client, let us say it is about stigma... he said I cannot go with a person to the*
523 *hospital because I will be seen that I am taken to the hospital. Just take my*
524 *contacts ...But since he is already into dose, I did that and he was faithful he*
525 *went for the service and he is continuing with the services well...I have never*
526 *attended with him and he does not want "(Female Treatment supporter, FGD,*
527 *dispensary)*

528
529 CHWs also expressed positive attitudes towards the family approach to TPT. They
530 reported liking 3HP as it is a shorter TPT and also liked the use of a treatment supporter
531 who in turn simplifies their work.

532
533 *"I would like to thank you about TPT and most importantly our clients were taking*
534 *a six months dose but now within just three months they have already completed*
535 *their dose, and before they used to take them on daily basis but now it is just*
536 *once in a week, so I am very grateful that TPT is just within a short period of*
537 *time, the client isn't getting tired" (Female CHW, IDI, dispensary)*

538
539 *"I really like this aspect because it is reducing some of my burdens and it makes*
540 *my work to be effective because if I miss my client and he has no treatment*
541 *supporter then not becomes very difficult for me to locate him, but if he has a*
542 *treatment supporter...it is easier to reach the client through [him]..." (Male CHW,*
543 *IDI, hospital)*

544
545 We sought to explore how the role of treatment supporter in the TPT study or the role of
546 CHW within family approach to TPT fits with their daily lifestyle and work
547 responsibilities. This also applied to how the use of TPT fits well with PLHIV lifestyle
548 and work responsibilities.

549
550 There were no changes in lifestyle or work responsibilities that were reported as a result
551 of taking 3HP. One of the PLHIV commented on how free he felt to take the drugs in
552 front of other people.

553 *"No, it hasn't changed anything because first I can take my medication even in*
554 *front of other people since not so many people knows about those medication,*
555 *when it is time even if there are guests at my house, I will just take my*
556 *medication, if they ask I can it is just the ulcers. I can say many people knows the*
557 *ARV but not TPT medication."* (Female PLHIV, IDI, dispensary)

558 Majority reported not having experienced lifestyle changes as a result of being a
559 treatment supporter. However, one of the treatment supporters stated not having the
560 time to converse with his patient about his treatment progress due to being busy with
561 work.

562 *"...you wish you could spend more time with the patient to understand their*
563 *challenges better. However, I am an entrepreneur, and in order to have a*
564 *conversation with the patient and get to know their challenges, I have to leave for*
565 *my business. You may plan to visit your patient today, but you find that you are*
566 *running out of time to be at home with your patient and understand their*
567 *challenges because you are late returning from your business."* (Male Treatment
568 supporter, FGD, hospital).

569 Few others complained how they had to leave work or lost their job because their client
570 was sick and had to be taken cared for.

571 *"The challenge I face is from the moment my patient started getting sick until*
572 *now. It requires me to be available all the time due to our temporary jobs. We*
573 *can't rest even during the weekend, so I ended up losing my job."* (Female
574 Treatment supporter, FGD, hospital)

575 Similar to PLHIV, no changes in work responsibilities were reported by CHWs because
576 they viewed that the changes did not relate to an additional work but rather change in
577 type of TPT education they had to provide.

578 *"Nothing has changed since this is the same thing we have been doing, the only*
579 *thing that has increased is providing education about TPT, they are the same*
580 *responsibilities we have been fulfilling because when we visit a PLHIV we must*

581 *perform TB screening, and these two things are going together. When I visit him,*
582 *I will speak about HIV, about TB screening as well as TPT" (Female CHW, IDI,*
583 hospital)

584

585 **Theme 5: Difficulties in implementing family approach to 3HP** 586 **(burden and opportunity cost)**

587 The two TFA constructs on burden and opportunity costs informed the development of
588 this theme that describes efforts and challenges encountered during the implementation
589 of different aspects of the family approach to 3HP/3RH provision.

590 Few of the PLHIV reported difficulties in selecting someone close to support them in
591 TPT because they feared disclosing their status to their relatives and perceived not to
592 have close friends who could keep a secret.

593 *"Till now still I haven't selected any [treatment supporter] because I am living on*
594 *my own, my relatives are very far...first since I was diagnosed positive, I decided*
595 *to stay away from my friends...I do have friends but a close one whom I can tell*
596 *my secret..." (Male PLHIV, IDI, hospital)*

597 Many reported experiencing drug side effects especially during the first month but were
598 tolerable. These include; reddish urine, nausea, fatigue and headache. One of the
599 PLHIV stated reaching out to his treatment supporter for advice as narrated in the quote
600 below:

601 *"...I was discharging a reddish urine, I even called my sister to ask her about it,*
602 *she told me that "remember now you are taking several medications, so you*
603 *should be ready to accept any changes" (Female PLHIV, IDI, dispensary)*

604 When probed about 3HP adherence challenges, treatment supporters reported patient
605 complaints about drug side effects such as nausea, fatigue and reddish urine. Additional
606 challenges included; not having enough money to support themselves or their clients
607 with transport fare to the clinic and for food costs, not being able to spend quality time

608 with their clients as well as not adhering to the exact time of taking their drugs. These
609 are illustrated in the quotes below;

610 *"...when my client started using them, he started having colored urine...I also*
611 *started being afraid because I thought it was blood, but later on I asked the*
612 *providers and they said no... he is progressing well"* (Male Treatment supporter,
613 FGD hospital)

614 *"...because we are living a bit far from here ...therefore, from there up to here and*
615 *back sometimes is difficult because I lack money for transport"* (Treatment
616 supporter, dispensary)

617 In regards to participation in health education sessions, treatment supporters
618 commented on their ability to support their clients during the first sessions but one of
619 them felt that they were rushed so that HCWs could accommodate long queues at the
620 clinic.

621 *"...when I went there, the health education sessions, we felt like they were*
622 *rushed. They had many customers to attend to and didn't have time to explain*
623 *properly"* (Female Treatment supporter, FGD dispensary)

624 They stated a tendency of their clients to arrive at the clinics late contrary to the agreed
625 meeting time thus, making it difficult for them to manage the clinic visit delays.
626 Moreover, they perceived their attendance to second and third sessions as unnecessary
627 as the information could be relayed to them by their clients. This is narrated in the below
628 quote;

629 *"Regarding health education ...we were together me and my client on the first*
630 *day, and that situation depends on relationship that you have built with your*
631 *client... your client will just go and bring explanations on what was said... you are*
632 *called to come and there is long queue it becomes difficult"* (Male Treatment
633 supporter, IDI, hospital)

634 CHWs stated that some of the PLHIV were unwilling to receive SMS alerts and some
635 who lived in remote areas were unable to receive the SMS texts timely as narrated in
636 the below quote:

637 *"When they are in remote areas that means they have poor network and they*
638 *won't receive the texts on time...when he returns to refill and you ask him if he*
639 *has been receiving the texts, he would say no while others who live around town,*
640 *they get them"* (Male CHW, IDI, hospital)

641 They reported challenges that they anticipate to occur when 3HP is scaled up for
642 programmatic use. These included difficulties in receipt of automated SMS reminders
643 for clients who; do not own mobile phones, reside in rural areas with network connection
644 problems, have a tendency of not reading text messages or are unwilling to accept
645 receipt of SMS alerts.

646 *"The challenge that I see maybe the client who is using a relative's phone, you*
647 *know the relative isn't always around, sometimes he is away on his busy*
648 *schedule, he might receive it today but he will call tomorrow to inform him or he*
649 *might neglect it, so the client won't get it as a reminder."* (Female CHW, IDI,
650 health center)

651 **Discussion**

652 This study sought to assess acceptability of a family approach to delivering 3HP among
653 PLHIV, TS and CHWs. According to TFA, an acceptable intervention is that which
654 beneficiaries consider it as "appropriate and satisfactory, based on anticipated or
655 experienced cognitive and emotional responses to the intervention" (19).

656 The findings indicate that participants were knowledgeable about vulnerability to TB,
657 TPT and family approach. They perceived the approach as important for supporting
658 3HP adherence and completion and believed that they could adhere and complete
659 treatment given their risk for developing TB. Although a majority of PLHIV experienced
660 mild self-limiting side effects, they had positive attitudes towards two components of the
661 family approach (i.e., having a family member and SMS reminders). This shows that

662 receiving support from a family member and SMS reminders was acceptable to the
663 majority. Perceived TB risk is also reported as a facilitator for 3HP acceptance in other
664 studies in Africa(20,21).

665 WHO advocates use of digital technologies for attaining the End TB strategy 2035
666 targets(22) and studies have shown that digital technologies enhance latent TB
667 treatment adherence and is acceptable to PLHIV(13,21,23). Reminder SMS could thus,
668 be a good option to improve 3HP adherence and attain desired completion rate among
669 PLHIV. However, caution is to be taken to ensure that confidentiality is preserved to
670 avoid unintentional HIV status disclosure.

671 We observed challenges among a minority of PLHIV who due to varied reasons were
672 unwilling or unable to identify a family member for treatment support, were unwilling to
673 receive SMS and a majority of treatment supporters who were unable to attend health
674 education together with their clients. These imply that the family approach is not a one
675 size fits all strategy and that diverse needs of PLHIV have to be considered. The family
676 approach may be adopted as a patient-centered approach to 3HP provision where
677 PLHIV who are unable to receive treatment support from family members can opt for
678 other significant others or receive SMS reminders. Provision of patient-centered TPT
679 services within differentiated service delivery models is called upon for improved TPT
680 coverage and increased completion rates(24–27)and is emphasized as the first pillar by
681 the WHO End TB strategy for achieving End TB targets (28) thus, customizing each of
682 the family approach delivery components to PLHIV preferences is expected to enhance
683 3HP adherence and completion.

684 Low participation of treatment supporters in second and third health education sessions
685 indicate that this component of the family approach does not align with their values and
686 lifestyles thus, is unacceptable. Furthermore, treatment supporters' perception that
687 participation was expensive and feelings that the sessions were rushed with HCWs due
688 to work burden might have influenced negative attitudes thus, discouraging
689 participation. This may influence the family approach to be generally ineffective given
690 receipt of limited training and counseling. Studies have indicated the effectiveness of

691 family involvement in supporting compliance to TB prevention and treatment when they
692 have positive attitudes and sufficient training (29–31).

693 Although family approach is shown to be acceptable to participants, the qualitative
694 design cannot provide conclusive arguments that it is effective in increasing 3HP
695 adherence and completion. Quantitative findings of the impact of family on 3HP uptake
696 and completion will be published separately.

697 **Conclusions**

698 Delivery of 3HP with support from family members and SMS reminders is widely
699 accepted by CHWs, PLHIVs and TS. However, the family approach is not a one size fits
700 all strategy thus, is recommended as a person-centered approach for 3HP delivery
701 among PLHIV. Restricting support from only family members was unacceptable and
702 attendance of all three health education sessions by treatment supporters may not be
703 feasible. Other relatively cheap platforms to engage and educate family members are
704 needed if the component on family involvement is to be adopted in programmatic
705 settings.

706

707

708 **Acknowledgements**

709 The authors are thankful for all participants who consented for discussions in the study.
710 We extend our gratitude to Nasra Abdul, Simeon Mwanyonga and Lonze Ndelwa for
711 supporting data collection and transcriptions. We commend the support received from
712 Dr Catherine Joachim on behalf of the Tanzania Ministry of Health for ensuring a
713 supportive environment for implementation of the study.

714 **Author contributions**

715 Study conceptualization: D.P., E.S., Data collection and analysis: D.P., E.S., K.M. Wrote
716 the first draft of the manuscript: D.P. Writing (critical review and editing): D.P., E.S,

717 K.M., L.M., C.M., A.N., W.O., R.K., I.S., A.R., S.A., N.E.N., All authors have read and
718 approved the final manuscript.

719

720

721

722

723

724

725

726

727

728

729 **References**

730 1. World Health Organization. Global Tuberculosis report 2022 [Internet]. 2022 [cited
731 2024 Jan 14]. Available from: [https://www.who.int/teams/global-tuberculosis-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)
732 [programme/tb-reports/global-tuberculosis-report-2022](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022)

733 2. Joint United Nations Programme on HIV/AIDS. The path that ends AIDS: UNAIDS
734 GLOBAL AIDS UPDATE 2023 [Internet]. [cited 2024 Jan 14]. Available from:
735 <https://thepath.unaids.org/>

736 3. UNAIDS. FACTSHEET-WORLD TUBERCULOSIS DAY 2022 [Internet]. 2022
737 [cited 2024 Jan 14]. Available from:
738 <https://www.unaids.org/en/resources/infographics/tuberculosis-and-hiv>

739 4. World Health Organization. Global tuberculosis report 2023 [Internet]. 2023 [cited
740 2024 Jan 14]. Available from: [https://www.who.int/teams/global-tuberculosis-](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023)
741 [programme/tb-reports/global-tuberculosis-report-2023](https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023)

- 742 5. World Health Organization. WHO consolidated guidelines on tuberculosis. Module
743 1: tuberculosis preventive treatment [Internet]. 2020 [cited 2024 Jan 14]. Available
744 from: <https://www.who.int/publications/i/item/9789240001503>
- 745 6. Stop TB Partnership. UNHLM on TB Key Targets & Commitments for 2022
746 [Internet]. 2018 [cited 2024 Jan 14]. Available from:
747 [https://www.stoptb.org/advocacy-and-communications/unhlm-tb-key-targets-and-](https://www.stoptb.org/advocacy-and-communications/unhlm-tb-key-targets-and-commitments)
748 [commitments](https://www.stoptb.org/advocacy-and-communications/unhlm-tb-key-targets-and-commitments)
- 749 7. Maokola WM, Ngowi BJ, Mahande MJ, Todd J, Robert M, Msuya SE. Impact of
750 Isoniazid Preventive Therapy on Tuberculosis incidence among people living with
751 HIV: A secondary data analysis using Inverse Probability Weighting of individuals
752 attending HIV care and treatment clinics in Tanzania. PLoS One. 2021 Jul 1;16(7
753 July).
- 754 8. MINISTRY OF HEALTH CDGEAC. NATIONAL GUIDELINES FOR THE
755 MANAGEMENT OF HIV AND AIDS [Internet]. 2019 Apr [cited 2024 Jan 14].
756 Available from: [https://nacp.go.tz/download/national-guidelines-for-the-](https://nacp.go.tz/download/national-guidelines-for-the-management-of-hiv-and-aids-april-2019/)
757 [management-of-hiv-and-aids-april-2019/](https://nacp.go.tz/download/national-guidelines-for-the-management-of-hiv-and-aids-april-2019/)
- 758 9. MINISTRY OF HEALTH, COMMUNITY DEVELOPMENT, GENDER EAC. The
759 United Republic of Tanzania. Development.
760 2019;7(5,371,780,231.09):2,274,923,575.00-29.08.
- 761 10. National Tuberculosis and Leprosy Programme. Report of the Tanzania Mid-Term
762 Review of the National Tuberculosis and Leprosy Programme Strategic Plan VI,
763 2020-2025. 2023.
- 764 11. Yanes-Lane M, Ortiz-Brizuela E, Campbell JR, Benedetti A, Churchyard G,
765 Oxlade O, et al. Tuberculosis preventive therapy for people living with HIV: A
766 systematic review and network meta-analysis. PLoS Med. 2021 Sep 1;18(9).
- 767 12. Shah R, Khakhkhar T, Modi B. Efficacy and Safety of Different Drug Regimens for
768 Tuberculosis Preventive Treatment: A Systematic Review and Meta-Analysis.
769 Cureus. 2023 Apr 27;

- 770 13. Lam CK, Pilote KMG, Haque A, Burzynski J, Chuck C, Macaraig M. Using video
771 technology to increase treatment completion for patients with latent tuberculosis
772 infection on 3-month isoniazid and rifapentine: An implementation study. *J Med*
773 *Internet Res.* 2018;20(11).
- 774 14. Walker RE, Bass S, Srinivas P, Miranda C, Johnson L, Pallotta AM. Evaluation of
775 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis
776 Infection. *Annals of Pharmacotherapy.* 2020 May 1;54(5):457–63.
- 777 15. Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, et al.
778 Completion of isoniazid–rifapentine (3HP) for tuberculosis prevention among
779 people living with HIV: Interim analysis of a hybrid type 3 effectiveness–
780 implementation randomized trial. *PLoS Med.* 2021 Dec 1;18(12).
- 781 16. Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-
782 administered versus directly observed once-weekly isoniazid and rifapentine
783 treatment of latent tuberculosis infection. *Ann Intern Med.* 2017 Nov
784 21;167(10):689–97.
- 785 17. Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, et al. Cost-
786 effectiveness of 3 months of weekly rifapentine and isoniazid compared with other
787 standard treatment regimens for latent tuberculosis infection: A decision analysis
788 study. *Journal of Antimicrobial Chemotherapy.* 2019 Jan 1;74(1):218–27.
- 789 18. Ministry of Health. NATIONAL TUBERCULOSIS AND LEPROSY STRATEGIC
790 PLAN VI 2020-2025 [Internet]. 2020 [cited 2024 Jan 15]. Available from:
791 <https://ntlp.go.tz/resources/national-strategic-plan/>
- 792 19. Sekhon M, Cartwright M, Francis JJ. Acceptability of healthcare interventions: An
793 overview of reviews and development of a theoretical framework. *BMC Health Serv Res.*
794 2017 Jan 26;17(1).
- 795 20. Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, et al.
796 Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among

- 797 people living with HIV (PLHIV) in Kampala, Uganda—patient and health worker
798 perspectives. *Implement SciCommun*. 2021 Dec 1;2(1).
- 799 21. Mapingure MP, Zech JM, Hirsch-Moverman Y, Msukwa M, Howard AA, Makoni T, et al.
800 Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe’s Fast Track HIV
801 treatment model: experiences from a pilot study. *J Int AIDS Soc* [Internet].
802 2023;26:26105. Available from:
803 <http://onlinelibrary.wiley.com/doi/10.1002/jia2.26105/full>[|https://doi.org/10.1002/jia2.26105](https://doi.org/10.1002/jia2.26105)
- 804 22. World Health Organization. DIGITAL HEALTH FOR END TB STRATEGY: AN AGENDA
805 FOR ACTION [Internet]. 2015 [cited 2024 Jan 27]. Available from:
806 <https://www.who.int/publications/i/item/WHO-HTM-TB-2015.21>
- 807 23. Wong YJ, Ng KY, Lee SWH. Digital health use in latent tuberculosis infection care: A
808 systematic review. Vol. 159, *International Journal of Medical Informatics*. Elsevier Ireland
809 Ltd; 2022.
- 810 24. Rabkin M, Howard AA, Ehrenkranz P, Fernandez LG, Preko P, Singh V, et al. Leveraging
811 differentiated HIV service delivery to expand tuberculosis preventive treatment: A call to
812 action. Vol. 24, *International Journal of Tuberculosis and Lung Disease*. International
813 Union Against Tuberculosis and Lung Disease (The Union); 2020. p. 165–9.
- 814 25. Boyd AT, Moore B, Shah M, Tran C, Kirking H, Cavanaugh JS, et al. Implementing TB
815 preventive treatment within differentiated HIV service delivery models in global programs.
816 *Public Health Action*. 2020 Oct 21;10(3):104–10.
- 817 26. Gonzalez Fernandez L, Casas EC, Singh S, Churchyard GJ, Brigden G, Gotuzzo E, et
818 al. New opportunities in tuberculosis prevention: implications for people living with HIV.
819 2020; Available from: <http://onlinelibrary.wiley.com/doi/10.1002/jia2.25438/full>
- 820 27. Hannah A, Dick M. Identifying gaps in the quality of latent tuberculosis infection care. *J*
821 *ClinTuberc Other Mycobact Dis*. 2020 Feb 1;18.
- 822 28. World Health Organization. WHO End TB Strategy [Internet]. 2015 [cited 2024 Jan 26].
823 Available from: [https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-](https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy)
824 [strategy](https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy)

- 825 29. Truzyan N, Crape B, Harutyunyan T, Petrosyan V. Family-Based Tuberculosis
826 Counseling Supports Directly Observed Therapy in Armenia: A Pilot Project. *J Tuberc*
827 *Res.* 2018;06(02):113–24.
- 828 30. Chen X, Du L, Wu R, Xu J, Ji H, Zhang Y, et al. The effects of family, society and national
829 policy support on treatment adherence among newly diagnosed tuberculosis patients: A
830 cross-sectional study. *BMC Infect Dis.* 2020 Aug 24;20(1).
- 831 31. Mariani H, Afriandi I, Setiawati EP, Gondodiputro S, Wiwaha G, Nataprawira HM, et al.
832 Tuberculosis Family Support Training's (TB FaST) Influence on Encouraging TB
833 Treatment Compliance. *Open Public Health J.* 2022 Sep 28;15(1).

834

835

836

837

838 **Supporting Information**

839

840 S1: In-depth interview guide_people living with HIV

841 S2: In-depth interview guide_community health workers

842 S3: Topic guide_treatment supporters

843

844

845

846

847